<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01391572</url>
  </required_header>
  <id_info>
    <org_study_id>2011ESO_FU_01</org_study_id>
    <nct_id>NCT01391572</nct_id>
  </id_info>
  <brief_title>A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer</brief_title>
  <official_title>A Randomized Phase II Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangsu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized phase II trial to estimate the optimal radiation volume of postsurgical
      radiation for patients with locoregionally advanced thoracic esophageal squamous cell
      carcinoma (T3-4, any N, M0).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Population:

      Thoracic esophageal squamous cell carcinoma after esophagectomy with at least 15 lymph nodes
      removed for adequate nodal staging.

      T3-4, any N, M0.

      Scheme:

      After esophagectomy, patients are firstly stratified by 2 factors: (1)number of lymph node
      metastasis (&lt;3 or &gt;=3) and (2)tumor resection status (R1 resection or R2 resection).

      Note: Pathological R0 resection status is required for this study. So here R1 and R2
      resection are not actually pathological status of resection, only clinical judgement by
      physician based on the chest-CT before esophagectomy.

      Then patients are randomized to 2 arms:

      Arm A:

      Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential
      chemotherapy (4 cycles).

      Arm B:

      Small field radiation (tumor bed only) + Sequential chemotherapy (4 cycles).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <description>To evaluate if the survival outcome of postsurgical radiation with a small target volume involved tumor bed only is not worse than a large volume (tumor bed and elective nodes) for patients with locoregionally advanced thoracic esophageal squamous cell carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <description>To evaluate the incidence rate of adverse events-especially radiation-induced lung toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure pattern</measure>
    <description>To evaluate the rationality of radiation target volumes by analyzing the therapeutic failure patterns especially by comparing the in-field and out-of-field recurrences.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>enlarge irradiation volume</intervention_name>
    <description>In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Small volume radiation</intervention_name>
    <description>In Arm B, postsurgical radiation target volume includes tumor bed only</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤70

          2. Performance status 0-1

          3. Weight is not less than 90% of it before operation

          4. Registration within 8 weeks after esophagectomy

          5. Histologically proven primary thoracic esophageal squamous cell carcinoma

          6. R0 resection and number of lymph nodes dissected ≥15 after esophagectomy

          7. Pathological stage of T3-4N0-3M0

          8. Chest and abdominal contrast enhanced CT within 6 weeks prior to registration(PET/CT
             scan is selective)

          9. Without supraclavicular nodes and abdominal regions nodes existed after surgery

         10. Without neo-adjuvant chemotherapy and radiotherapy

         11. WBC≥ 4.0X109/L ,Absolute neutrophil count (ANC) ≥ 2.0X109/L

         12. Platelets ≥ 100X109/L

         13. Hemoglobin ≥ 90g/L(without blood transfusion)

         14. AST (SGOT)/ALT (SGPT) ≤ 2.5 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of
             normal

         15. Creatinine ≤ 1.5 x upper limit of normal

         16. Sign study-specific informed consent prior to study entry

        Exclusion Criteria:

          1. Multiple primary esophageal tumors

          2. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible).

          3. Severe, active comorbidity, defined as follows:

             3.1 Unstable angina and/or congestive heart failure requiring hospitalization within
             the last 3 months 3.2 Transmural myocardial infarction within the last 6 months 3.3
             Acute bacterial or fungal infection requiring intravenous antibiotics at the time of
             registration 3.4 Chronic obstructive pulmonary disease exacerbation or other
             respiratory illness requiring hospitalization or precluding study therapy at the time
             of registration 3.5 Acquired immune deficiency syndrome (AIDS) based upon current CDC
             definition; note, however, that HIV testing is not required for entry into this
             protocol. The need to exclude patients with AIDS from this protocol is necessary
             because the treatments involved in this protocol may be significantly
             immunosuppressive.

          4. Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception.

          5. Prior systemic chemotherapy, prior radiation therapy or prior target drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-Long Fu, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu-Wei Cai, M.D., Ph.D.</last_name>
    <phone>8621-64175590</phone>
    <phone_ext>1504</phone_ext>
    <email>birdhome2000@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu-Wei Cai, M.D., Ph.D.</last_name>
      <phone>8621-64175590</phone>
      <phone_ext>1504</phone_ext>
      <email>birdhome2000@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Xiao-Long Fu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xiao-Long Fu / Professor</name_title>
    <organization>Fudan University Cancer Center</organization>
  </responsible_party>
  <keyword>thoracic esophageal squamous cell carcinoma</keyword>
  <keyword>esophagectomy</keyword>
  <keyword>radiation</keyword>
  <keyword>tumor bed</keyword>
  <keyword>elective nodal irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

